miR-148a alleviates cardiac dysfunction, immune disorders, and myocardial apoptosis in myocardial ischemia–reperfusion injury by targeting pyruvate dehydrogenase kinase 4 [41]. This evidence concerns the gene PDK4 and immune system disorder.